Medicine Center and Wellness Circle - Pharmacy Practioner Leadership

Health News Report Reprinted 2008-01-29

New Report Predicts that Novartis' Diovan, Glivec/Gleevec and Zelmac/
Zelnorm will Continue to Show Healthy Sales Growth

Saturday, August 11, 2007


Aug. 3, 2007 (M2 Communications Ltd. delivered by Newstex) --

Research and Markets (http://www.researchandmarkets.com/reports/
c64757) has announced the addition of Novartis: Performance, Products,
Pipeline and Potential to their offering

Pharmaceutical company intelligence reports provide a full review of
the company's activities together with five-year sales forecasts for
its key products. The company's financial performance is covered in-
depth, from its latest results to a complete analysis of
itscccccccclatest full fiscal year and an outlook for the future. A
section on company strategy covers mergers, acquisitions and
divestitures, key agreements, products and R&D. An overview of key
products and R&D is followed by a comprehensive review of the
company's product portfolio and research and development pipeline by
therapeutic area. In addition, supplementary appendices provide more
in-depth information on financials, agreements and corporate events.

Following the merger of Ciba and Sandoz, the spin-off of the
Agribusiness sector and the sale of the remaining activities of the
Industry division, Novartis has become a leading company in the life
sciences field and has operations in approximately 140 countries
worldwide. Novartis is currently organised into the four divisions of
Pharmaceuticals, Consumer Health, Sandoz and Vaccines &
Diagnostics, created following the acquisition of Chiron Corporation.
Within Pharmaceuticals, the company's current growth drivers include
Diovan (valsartan), Glivec/Gleevec (imatinib), Femara (letrozole) and
Zometa (zoledronate).

Novartis' current pharma growth drivers together account for
approximately 38 per cent of total pharma sales, and we predict that
Diovan, Glivec/Gleevec and Zelmac/Zelnorm will continue to demonstrate
substantial sales growth within the medium term. In addition, the
recent launch and approval of a selection of products which include
Exjade (deferasirox), Prexige (lumiracoxib), Xolair (omalizumab),
Exforge (valsartan+amlodipine), Lucentis (ranibizumab) and Tekturna
(aliskiren), should offset the decline in sales of a number of
Novartis' strategic products. However, this confidence is tempered by
the recent setbacks to the fortunes of Zelnorm/Zelmac (tegaserod) and
Tekturna.

As a research-intensive company which has benefited from the Chiron
acquisition, Novartis has a strong pharma pipeline with a total of 138
compounds under development. Of particular note a Galvus
(vildagliptin), filed for Type II diabetes in the US and the EU; and
fingolimod under Phase III development for multiple sclerosis.
However, Novartis still faces some hurdles since the approvable letter
for Galvus has allowed Merck's Januvia a head start in the important
US market.

Novartis' major company strategy is based on innovation and achieving
a leading position in the healthcare sector. To this end, in 2005, the
Pharmaceuticals division further expanded its research operations and
this process continued in 2006. Pharmaceuticals remains Novartis'
largest and most profitable business, with the Cardiovascular and
Oncology franchises continuing as the leading therapeutic areas.
Chiron's pharmaceutical operations are being integrated into the
Pharmaceuticals division.

In the light of government cost containment measures, Novartis intends
to develop new growth platforms such as vaccines (which will reduce
costs through disease prevention) and expand its generic business (so
capitalising on governments' promotion of generics).

This new strategic analysis report Novartis: Performance, Products,
Pipeline and Potential, provides a complete and critical review of the
company and includes unique and independent assessments and forecasts
of key products. The report is updated on a quarterly basis. Buyers of
the web edition receive quarterly reports for a year. Buyers of the
print/pdf editions receive the latest version. All formats are the
same price.

EXECUTIVE SUMMARY

A detailed and comprehensive overview of current financial position,
company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS

Key product analysis and forecasting

Cardiovascular and Metabolism

Diovan/Co-Diovan (valsartan)

Exforge (amlodipine+valsartan)

Lescol (fluvastatin)

Lotrel (amlodipine+benazepril)

Tekturna (aliskiren)

Oncology/Haematology

Exjade (deferasirox)

Femara (letrozole)

Glivec/Gleevec (imatinib)

Sandostatin (octreotide)

Zometa/Aclasta (zoledronic acid)

Neuroscience

Comtan (entacapone)

Exelon (rivastigmine)

Ritalin/Focalin (methylphenidate)

Stalevo (entacapone)

Trileptal (oxcarbazepine)

Arthritis/Bone

Miacalcic/Miacalcin (synthetic salmon calcitonin)

Prexige (lumiracoxib)

Voltaren/Cataflam (diclofenac sodium)

Gastrointestinal

Zelnorm/Zelmac (tegaserod)

Respiratory/Dermatology

Elidel (pimecrolimus)

Foradil (formoterol fumarate)

Lamisil (terbinafine)

Xolair (omalizumab)

Transplantation/Immunology

Certican (everolimus)

Sandimmun/Neoral (ciclosporin)

Infectious Diseases

Famvir/Denavir (famciclovir)

Sebivo/Tyzeka (telbivudine)

Ophthalmics

Lucentis (ranibizumab)

Visudyne (verteporfin)

OPERATIONAL DATA

A wealth of background and detail

A full 5-year financial performance assessment

Key corporate events

Key agreements

Infrastructure

Subsidiaries

For more information visit http://www.researchandmarkets.com/reports/c64757

Source: Espicom Business Intelligence

(Comments on this story may be sent to )


Newstex ID: MCOM-0001-18828037


Delivered by Newstex LLC


via theFinancials.com

Giuen Holding Ltd. wellness retail division

Goteborgsvagen 1.

SE:434 00 Kungsbacka

Int. Call +46 (0) 705474830

Office: 09.00-20.00


Voltaren T Gel

Voltaren Pharmacy Information

http://astore.amazon.com/wellnessretaildivision-20



Associate Website

Celebrities Fitness Systems
http://www.redcarpetready.com/home.html?hop=vibe1